SAR422459

Phase 1/2Terminated

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Stargardt's Disease

Conditions

Stargardt's Disease

Trial Timeline

Jun 8, 2011 → Aug 16, 2019

NCT ID

NCT01367444

About SAR422459

SAR422459 is a phase 1/2 stage product being developed by Sanofi for Stargardt's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01367444. Target conditions include Stargardt's Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01367444	Phase 1/2	Terminated	Jun 8, 2011	Aug 16, 2019	Stargardt's Disease

Competing Products

6 competing products in Stargardt's Disease

See all competitors

Product	Company	Stage	Hype Score
MA09-hRPE	Astellas Pharma	Pre-clinical	26
MA09-hRPE	Astellas Pharma	Phase 1/2	32
avacincaptad pegol + Sham	Astellas Pharma	Phase 2	35
MA09-hRPE	Astellas Pharma	Phase 1/2	32
hESC-RPE	Astellas Pharma	Pre-clinical	26
Long term follow up in all patients who received SAR422459 in previous study TDU13583	Sanofi	Phase 2	39